8-K: LifeVantage Q3 FY26 Results Show Revenue Decline

LifeVantage Corporation reported a 25.2% decrease in third-quarter fiscal 2026 revenue to $43.7 million, primarily due to lower sales of its MindBody GLP-1 System.

Summary

• LifeVantage Corporation announced its financial results for the third quarter of fiscal year 2026, ending March 31, 2026.
• Revenue for the quarter was $43.7 million, a significant decrease of 25.2% compared to the same period last year.
• Net income per diluted share was $0.11, down from $0.26 in the prior year's third quarter.
• Adjusted EBITDA decreased to $3.2 million from $6.4 million in the prior year.
• The company experienced declines in both the Americas (down 28.9%) and Asia/Pacific & Europe (down 7.7%) regions.
• The decrease in revenue was attributed to lower sales of the MindBody GLP-1 System, partially offset by the addition of LoveBiome.
• The company declared a cash dividend of $0.05 per common share, an 11.1% increase from the previous quarter.
• LifeVantage anticipates fiscal 2026 revenue, adjusted EBITDA, and adjusted earnings per share to be near the lower end of previously issued guidance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant revenue and profit declines, a shrinking active account base, and guidance at the lower end of expectations, despite a modest dividend increase.

Positives

• The company declared a cash dividend of $0.05 per common share, representing an 11.1% increase from the previous quarterly dividend.
• Despite revenue headwinds, the company maintained a strong balance sheet and cash position with no debt outstanding.
• Share repurchases continued, with approximately $1.6 million spent in the first nine months of fiscal 2026 under a $60 million program.
• The company is in a compelling position in the rapidly expanding health and wellness market with significant growth potential.

Negatives

• Revenue for the third quarter of fiscal 2026 was $43.7 million, a 25.2% decrease from $58.4 million in the prior year.
• Net income per diluted share fell to $0.11 from $0.26 in the prior year's third quarter.
• Adjusted EBITDA was $3.2 million, down from $6.4 million in the prior year's third quarter.
• Revenue in the Americas decreased by 28.9%, and revenue in Asia/Pacific & Europe decreased by 7.7%.
• Gross profit margin decreased to 79.0% from 81.0% due to an allowance for inventory obsolescence and increased shipping costs.
• Selling, general, and administrative (SG&A) expenses increased as a percentage of revenue to 31.7% from 29.2%.
• Active accounts (consultants and customers) decreased by 22.1% year-over-year.
• The company expects fiscal 2026 financial performance to be near the lower end of previously issued guidance.

Risks

• Further deterioration to the global economic and operating environments.
• Risks and uncertainties discussed in greater detail in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q under the caption 'Risk Factors'.

Future Outlook

The Company anticipates fiscal 2026 revenue, adjusted EBITDA, and adjusted earnings per share to be close to the lower end of its previously issued guidance range. The full-year tax rate is expected to be approximately 18% to 20%. This guidance reflects current business trends and strategic initiatives.

Management Comments

• "Third quarter results were softer than we anticipated as lower sales of our MindBody GLP-1 System were only partially offset by the addition of LoveBiome," said Michael Beindorff, Interim CEO of LifeVantage.
• "Despite top-line headwinds, we remained focused on managing expenses and allocating capital, enabling us to continue repurchasing shares while maintaining a strong balance sheet and cash position."
• "That said, we are not satisfied with our performance and are laser focused on making the changes necessary to improve results going forward."
• "With our science-backed approach to nutrigenomics, diversified product portfolio, passionate consultant community, and strong financial foundation, LifeVantage is in a compelling position in the rapidly expanding health and wellness market with significant growth potential ahead, and we intend to realize that potential."

Industry Context

StockSavvy.ai notes that LifeVantage's results reflect challenges in the direct selling and health & wellness sector, particularly with product-specific sales declines impacting overall revenue. The company's focus on nutrigenomics and a diversified product portfolio positions it within a growing market, but execution on strategic initiatives is critical to reversing current trends.

Comparison to Industry Standards

• The revenue decline of 25.2% is significantly worse than the average growth seen in the broader health and wellness market, which has generally experienced positive growth.
• Competitors in the direct selling space, such as Amway or Herbalife, have also faced challenges but often report more stable or growing revenue streams, indicating potential issues with LifeVantage's specific product strategy or execution.
• The decrease in gross profit margin, while still relatively high at 79.0%, is a concern when compared to industry leaders who often maintain margins above 80% through efficient supply chain management and premium product pricing.

Stakeholder Impact

• Shareholders may be concerned by the significant decline in revenue and profitability, potentially impacting stock value.
• Consultants and customers may be affected by the decrease in active accounts and the company's performance, potentially impacting their earnings or product satisfaction.
• Employees may face uncertainty due to the company's focus on making changes to improve results.

Next Steps

• Focus on making necessary changes to improve results going forward.
• Continue to manage expenses and allocate capital.
• Realize the significant growth potential in the health and wellness market through strategic initiatives.

Key Dates

Recommendation

While the results are significantly worse than the prior year and guidance is at the low end, the company has a strong balance sheet, no debt, and is increasing its dividend. The focus on strategic changes and potential for growth in the health and wellness market warrants a hold rating pending evidence of a turnaround.

Keywords

LifeVantage, Financial Results, Q3 FY26, Revenue Decline, Health and Wellness, Nutrigenomics, MindBody GLP-1 System, Dividend